Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $13.0 to $26.5 for Pfizer over the last 3 months.

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $30.0 for Pfizer during the past quarter. Looking at the volume ...

Pfizer Inc. has re-entered the obesity drug sector by acquiring Metsera, Inc., having successfully outmaneuvered six other bidders. Despite skepticism over Pfizer's recent acquisitions, Metsera's ...

Nine of fifteen Barron's Better Bets (BBB) 'safer' high-yield dividend stocks are currently attractively priced, including ...

Michael Burry shorts Nvidia and Palantir, stoking AI bubble fears. Scion’s $1.1B puts shake markets. NVDA and PLTR rally over ...

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling ...

Michael Burry, the investor made famous by The Big Short for predicting the 2008 financial crisis, has once again captured public attention with his latest moves on Wall Street. This time, he is ...

CorMedix CRMD is expected to report its third-quarter 2025 earnings results soon. The Zacks Consensus Estimate for sales and ...

Eli Lilly and Novo Nordisk are expected to announce price reductions for their weight-loss drugs as part of the TrumpRx ...

Risky assets slid, with tech stocks and cryptocurrencies bearing the brunt of the selling, after long-simmering concerns ...